Table 1.
Demographic and clinical characteristics of the study sample
| Characteristics | CBT (n = 99) | I-CBT (n = 98) |
|---|---|---|
| Sociodemographics | ||
| Age, years | 33.7±11.8 | 33.9±11.6 |
| Sex, female, % | 62 | 62 |
| Partner, yes, % | 60 | 68 |
| Children, yes, % | 35 | 30 |
| Employment, yes, % | 65 | 76 |
| OCD | ||
| Age at onset | 16.9±9.8 | 15.1±8.2 |
| Duration of illness | 16.8±10.6 | 18.8±12.0 |
| Overall severity (Y-BOCS) | 24.9±4.4 | 24.5±4.9 |
| Obsessions (Y-BOCS) | 12.1±2.6 | 11.9±2.8 |
| Compulsions (Y-BOCS) | 12.9±2.6 | 12.7±2.9 |
| Treatment credibility and expectancy | ||
| Treatment credibility (CEQ) | 19.5±4.6 | 20.1±3.6 |
| Treatment expectancy (CEQ) | 16.1±5.2 | 16.7±4.3 |
| Secondary outcomes | ||
| Treatment tolerability (TAAS) | 47.7±7.7 | 51.0±6.0 |
| Insight (OVIS) | 5.0±1.4 | 5.0±1.4 |
| QoL (EQ-5D utility score) | 0.7±0.2 | 0.7±0.2 |
| Functional impairment (SDS) | 13.8±7.3 | 14.6±8.0 |
| Depression (BDI) | 16.6±9.5 | 15.4±9.6 |
| Anxiety (BAI) | 17.0±9.7 | 16.2±9.7 |
| Comorbidity, previous treatment, and current treatment with medication | ||
| Current comorbidity, yes, % | 59 | 47 |
| Current comorbid disorder, n | 1.0±1.2 | 0.7±1.1 |
| Current antidepressants, yes, % | 38 | 37 |
| Current benzodiazepines, yes, % | 8 | 10 |
| Current atypical antipsychotics, yes, % | 3 | 5 |
| Previous treatment for OCDa, yes, % | 36 | 38 |
Values represent means ± SD or n (%). TAAS was statistically significantly higher for IBA compared to CBT (t(187) = −3.30, p = <0.001). There were no statistically significant differences between the treatment groups on the other variables.
CBT, cognitive behavioral therapy; I-CBT, inference-based cognitive behavioral therapy; OCD, obsessive-compulsive disorder; Y-BOCS, Yale-Brown Obsessive Compulsive Scale; OVIS, Overvalued Ideation Scale; EQ-5D, EuroQol five-dimensional questionnaire; SDS, Sheehan Disability Scale; BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory.
aAt least 600-min CBT.